Atypical Endometrial Hyperplasia Clinical Trial
Official title:
Department of Obstetrics & Gynecology ，Peking University People's Hospital
To construct a prediction model of progesterone sensitivity in patients with endometrial cancer treated with fertility preservation
After diagnosed of early endometrial carcinoma (EEC) or atypical endometrial hyperplasia (AEH) by hysteroscopy, patients meet the study criteria will be enrolled. Patients will receive MPA (Medroxyprogesterone acetate) 250-500mg or MA (megestrol acetate) 160-320mg by mouth daily. Then hysteroscopy will be used to evaluate the endometrial condition every 3 months, and intra-operative findings will be recorded. Hysteroscopy will continue until pathology confirms complete response. Complete response (CR) is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (PR) is defined as regression to hyperplasia with or without atypic; stable disease (SD) is defined as the persistence of the disease; and progressive disease (PD) is defined as the appearance of higher pathological progression, or myometrial invasion, or extra-uterine metastasis. Continuous therapies will be needed in PR or SD. Patients with PD will be recommended for hysterectomy. During each hysteroscopy, the intraoperative residual tissues were sent to the laboratory of College of Future Science and Technology of Peking University for culture as Patient-derived tumor-like cell clusters (PTC), and the content of lipids (lipid droplet size and cholesterol content) was measured by stimulated Raman scattering imaging and recorded. After collecting the data of 148 cases, the prediction model was constructed. Then the model is validated in the validation set composed of 96 new cases. In order to determine the accuracy and sensitivity of the model. If a patient has achieved a pathological complete response and a high lipid content is detected in the tissue by stimulated Raman scattering imaging, we will follow up for subsequent recurrence. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02397083 -
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT04491682 -
Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT00788671 -
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT04385667 -
LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT01943058 -
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
|
Phase 2 | |
| Withdrawn |
NCT04683237 -
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
| Completed |
NCT00483327 -
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
|
Phase 2 | |
| Recruiting |
NCT05316493 -
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
| Completed |
NCT03241888 -
Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06390904 -
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06379113 -
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05316935 -
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05172999 -
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05675787 -
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
|
Phase 2 | |
| Active, not recruiting |
NCT03671811 -
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
|
Phase 2 | |
| Completed |
NCT00490087 -
Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women
|
Phase 3 | |
| Terminated |
NCT04607252 -
Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05051722 -
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
|
||
| Active, not recruiting |
NCT00892866 -
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
|
N/A | |
| Recruiting |
NCT03463252 -
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
|
Phase 2/Phase 3 |